ClinicalTrials.gg
RecruitingNCT06870331PRO-GIDSCIUpdated Oct 3, 2025

The Effect of Probiotic and Prebiotic Supplementation on Gastrointestinal Health in Individuals With Chronic Spinal Cord Injury

An interventional study of Probiotic and Prebiotic in Spinal Cord Injury, sponsored by Swiss Paraplegic Research, Nottwil. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Swiss Paraplegic Research, Nottwil · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Spinal Cord Injuries by Swiss Paraplegic Research, Nottwil — 8 open to participants now, 8 under way, none of them phase 3. Spinal Cord Injuries · Swiss Paraplegic Research, Nottwil.

Planned enrollment
2nd of 24
50 · median 20
Started
2025
with 3 others
No phase
20 of 47
6 open now
Registered
41st of 47
by date

Among the 47 studies in Spinal Cord Injuries by Swiss Paraplegic Research, Nottwil, this one is the 2nd largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2025, is one of 20 with no phase, and was the 41st registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

8 of the 47 studies in Spinal Cord Injuries by Swiss Paraplegic Research, Nottwil are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Spinal Cord Injuries by Swiss Paraplegic Research, Nottwil, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effect of probiotic and prebiotic supplementation in individuals with chronic spinal cord injury experiencing gastrointestinal complaints.

The main questions this trail aims to answer are:

  • what are the effects of the supplementation on gastrointestinal symptoms?
  • what are the effects of the supplementation on gut microbiome composition?
  • what are the effects of the supplementation on inflammatory serum markers?
  • what are the effects of the supplementation on gastrointestinal transit time?

Participants will:

  • take either the probiotic or prebiotic supplement daily for eight weeks, followed by a four-week "wash-out period" (= no intake of either supplement) and a subsequent eight-week intake of the other supplement.
  • visit the study center for four appointments, during which various measurements will be performed.
03

Conditions studied

  • Spinal Cord Injury

Keywords

  • probiotic
  • prebiotic
  • gastrointestinal health
  • microbiome
  • dietary supplement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≥ 18 years
  • Sex: male and female.
  • Chronic SCI (>1 year post-injury)
  • Individuals with para- and tetraplegia (American Spinal Cord Injury (ASIA) Impairment Scale (AIS) score A-D)
  • Having significant gastrointestinal complaints, indicated with "yes" at screening and by a GIQLI questionnaire score below 110 at baseline
  • Signed written

Exclusion criteria

Exclusion Criteria (at screening):

  • Antibiotic use within the last four weeks before starting the study
  • Major dietary changes within the last four weeks before starting the study, such as initiating a vegan or ketogenic diet
  • Presence of medical conditions, including Crohn's disease, diagnosed eating or gastrointestinal disorders, assessed on an individual basis
  • Intake of significant concomitant medication, including immunomodulating therapy, mesalazines, or , assessed on an individual basis
  • Concurrent participation in other clinical trials investigating or potentially affecting GI health
  • Insufficient German language skills to follow the study procedures
  • Pregnancy (anamnestic)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Probiotic intervention

    Probiotics add beneficial bacterial strains to the gut, which can restore microbial balance.

    Dietary Supplement: Probiotic

  • Active comparator
    Prebiotic intervention

    Prebiotics, such as oat bran, selectively promote the growth of beneficial gut bacteria, particularly butyrate-producing species.

    Dietary Supplement: Prebiotic

Interventions

  • Dietary supplementProbiotic

    Participants will take one sachet BIOTICS-G (Burgerstein, Switzerland, 2.5 g) daily for eight weeks. The supplement contains 14 bacterial strains with a total viable cell count of 2.5 billion colony-forming units per sachet.

  • Dietary supplementPrebioticsStudies of PrebioticsPrebiotics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will take 5 g of oat bran (Naturaplan Bio Haferkleie, Coop, Switzerland) daily for eight weeks.

06

What researchers measure

Primary outcomes

  1. Gastrointestinal symptoms

    Change in gastrointestinal symptoms using the Gastrointestinal Quality of Life (GIQLI) questionnaire.

    Time frame: Before and after eight weeks of intake of the dietary supplement.

Secondary outcomes

  1. Gut microbiome composition

    Change in gut microbiome composition, assessed using a stool sample.

    Time frame: Before and after eight weeks of intake of the dietary supplement.

  2. Inflammatory markers

    Change in serum inflammatory markers, assessed by a blood sample.

    Time frame: Before and after eight weeks of intake of the dietary supplement.

  3. Gastrointestinal transit time

    Change in gastrointestinal transit time, assessed by the blue dye test (time from ingestion to first appearance of blue food dye in the stool).

    Time frame: Before and after eight weeks of intake of the dietary supplement.

Other outcomes

  1. Side effects

    Occurrence of side effects of the supplementation, assessed by questioning.

    Time frame: After the eight weeks of intake of the dietary supplement.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Trunz J, Schmandt C, Hertig-Godeschalk A, Glisic M, Stoyanov J, Perret C. Probiotic and Prebiotic Supplementation for Gastrointestinal Discomfort in Chronic Spinal Cord Injury (PRO-GIDSCI): A Randomized Controlled Crossover Trial Protocol. Methods Protoc. 2026 Jan 17;9(1):14. doi: 10.3390/mps9010014. PubMed 41562992 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 22 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 11, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06870331
Lead sponsor
Swiss Paraplegic Research, Nottwil
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Aug 11, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 3, 2025

Study contacts

Claudio Perret, Prof. Dr.
Contact
claudio.perret@paraplegie.ch
+41419396650
Anneke Hertig-Godeschalk, PhD
Contact
anneke.hertig@paraplegie.ch
+41419396603
Jivko Stoyanov, Prof. Dr.
study director · Swiss Paraplegic Research, Nottwil

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion